Consulting services: Kennedy Trust

Oxentia reviewed the patent portfolio for the Kennedy Trust, a UK charity that funds of the Kennedy Institute of Rheumatology. The Kennedy Trust holds a over 100 granted patents from world leading scientists including the team that developed infliximab, the first anti-TNF therapy.

Annual maintenance costs for the portfolio were considerable, as were the skills required to successfully commercialise the assets. The project has involved a detailed analysis of each patent family to assess commercial potential and translational probabilities of success, resulting in a trimming of the portfolio that confers a significant cost-saving to the client.

We have then been also supporting the client in the commercialisation of those patent families with the greatest market opportunity through our network of licensees.


Ready to get in touch?

Contact Us
© Oxford University Innovation